Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $53,513.10 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 3,214 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $16.65, for a total value of $53,513.10. Following the sale, the insider directly owned 120,399 shares of the company’s stock, valued at $2,004,643.35. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Gwenn Hansen also recently made the following trade(s):

• On Friday, January 30th, Gwenn Hansen sold 4,895 shares of Nurix Therapeutics stock. The stock was sold at an average price of $16.60, for a total value of $81,257.00.

Nurix Therapeutics Stock Up 0.5%

Shares of NRIX traded up $0.09 during midday trading on Thursday, reaching $16.70. 840,236 shares of the stock were exchanged, compared to its average volume of 1,138,983. Nurix Therapeutics, Inc. has a 12-month low of $8.19 and a 12-month high of $22.50. The firm has a 50 day simple moving average of $15.82 and a 200-day simple moving average of $15.99. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -5.28 and a beta of 1.97.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $14.25 million. Research analysts expect that Nurix Therapeutics, Inc. will post -2.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

NRIX has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Tuesday, April 21st. Piper Sandler raised their price objective on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. Wells Fargo & Company cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Thursday, April 9th. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the company an “overweight” rating in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada raised their price objective on Nurix Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.46.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its position in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after buying an additional 1,190 shares during the period. California State Teachers Retirement System increased its position in Nurix Therapeutics by 2.2% in the 4th quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock worth $1,290,000 after buying an additional 1,476 shares during the period. Intesa Sanpaolo Wealth Management bought a new position in Nurix Therapeutics in the 4th quarter worth approximately $31,000. Royal Bank of Canada increased its position in Nurix Therapeutics by 17.6% in the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after buying an additional 1,623 shares during the period. Finally, Arizona State Retirement System increased its position in Nurix Therapeutics by 8.2% in the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after buying an additional 1,674 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.